SUN bioscience

About:

SUN bioscience creates advanced cell culture platforms.

Top Investors: Possible Ventures, Acequia Capital (AceCap), MassChallenge, FOUNDER.org, Foundation for Innovation and Technology (FIT)

Description:

SUN bioscience is enabling personalized medicine through patient-specific organoids cultured on SUN’s proprietary high-throughput 3D microwell platform. Organoids are self-organizing 3D miniature tissues with organ-mimicking functions that are grown from stem cells. They are powerful human in vitro models for assessing pharmaceutical efficacy and toxicity early on in drug development. The SUN technology is solving the problems that organoid culture today cannot be scaled and automated. This will introduce a new area of drug discovery where we can understand drug performance outside of an animal or a human being.

Total Funding Amount:

$756000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Lausanne, Vaud, Switzerland

Founded Date:

2015-01-01

Contact Email:

info(AT)sunbioscience.ch

Founders:

Nathalie Brandenberg, Sylke Hoehnel

Number of Employees:

1-10

Last Funding Date:

2021-05-11

IPO Status:

Private

Industries: